Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
CI 994 is an orally active class I histone deacetylase (HDAC) inhibitor (Ki values are 0.41, 0.75, >100 and >100 μM for HDAC1, HDAC3, HDAC6 and HDAC8 respectively). Mediates G1 cell cycle arrest, inhibits proliferation and induces apoptosis in vitro and in vivo. Increases neuroplasticity during memory extinction. Also increases efficiency of hepatic differentiation of hPSCs
CI 994 is also offered as part of the Tocriscreen 2.0 Max, Tocriscreen Antiviral Library, Tocriscreen Epigenetics Library and Tocriscreen Stem Cell Library. Find out more about compound libraries available from Tocris.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 269.3. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.71 mL||18.57 mL||37.13 mL|
|5 mM||0.74 mL||3.71 mL||7.43 mL|
|10 mM||0.37 mL||1.86 mL||3.71 mL|
|50 mM||0.07 mL||0.37 mL||0.74 mL|
References are publications that support the biological activity of the product.
Beckers et al (2007) Distinct pharamacologcial properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int.J.Cancer 121 1138 PMID: 17455259
Gräff et al (2014) Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 156 261 PMID: 24439381
Kraker et al (2003) Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benamide] in HCT-8 colon carcinoma. Mol.Cancer Ther. 2 401 PMID: 12700284
If you know of a relevant reference for CI 994, please let us know.
Keywords: CI 994, CI 994 supplier, Histone, deacetylases, inhibitors, inhibits, HDAC, Class, I, CI994, epigenetics, HDAC1, HDAC2, HDAC3, HDAC8, hepatocyte, differentiation, N-acetyldinaline, HDACs, Hepatocyte, Stem, Cells, 2952, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for CI 994. Do you know of a great paper that uses CI 994 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review CI 994 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.